Table 3.
Data extraction of the selected randomised trials
| Sl. No | Author | Year | Country | Mean age (SD) | Type of study | Gender | No of groups | No of patients per group | Administration time | Administration route | Dose of dexamethasone | Pell & Gregory Classification |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pappalardo et al. [12] | 2007 | Italy | 26.45 (4.2) | Parallel | 52M;48F | A | 20 | Before suturing | EA | 10 mg | Class I B |
| B | 20 | (unclear) | SM | 10 mg | ||||||||
| C | 20 | Intra-op | IV | 4 mg | ||||||||
| D | 20 | Intra-op | IM (Unclear) | 8 mg | ||||||||
| E | 20 | unclear | unclear | NA | ||||||||
| 2 | Antunes et al. [13] | 2011 | Brazil | 21 (5.4) | Parallel | 13M;5F | A | 18 | Pre-op | IM (masseter) | 8 mg | Class II B |
| 16M;4F | B | 20 | Pre-op | Oral | 8 mg | |||||||
| 8M;14F | C | 22 | NA(Control) | NA(Control) | NA(Control) | |||||||
| 3 | Majid et al [6] | 2011 | Iraq | 26.7 (6.3) | Parallel | 5M;5F | A | 10 | Post-op | SM | 4 mg | Class II/III A/B/C |
| 7M;3F | B | 10 | Post-op | IM (Unclear) | 4 mg | |||||||
| 4M;6F | C | 10 | NA(Control) | NA(Control) | NA(Control) | |||||||
| 4 | Majid et al [14] | 2013 | Iraq | 25.6(5.9) | Parallel | 8M;4F | A | 12 | Post-op | IM (deltoid) | 4 mg | Class II/III A/B/C |
| 8M;4F | B | 12 | Post-op | IV | 4 mg | |||||||
| 4M;8F | C | 12 | Post-op | PO | 4 mg | |||||||
| 4M;7F | D | 12 | Post-op | SM | 4 mg | |||||||
| 3M;9F | E | 12 | Post-op | EA | 4 mg (powder) | |||||||
| 4M;8F | F | 12 | NA(Control) | NA(Control) | NA(Control) | |||||||
| 5 | Bhargava et al. [4] | 2014 | India | 24.1(4.3) | Parallel | 34M;26F | A | 10 | NA(Control) | NA(Control) | NA(Control) | Class II B |
| B | 10 | Pre-op | PTM(Twin mix) | 4 mg | ||||||||
| C | 10 | Pre-op | SM | 4 mg | ||||||||
| D | 10 | Pre-op | IM | 4 mg | ||||||||
| E | 10 | Pre-op | IV | 4 mg | ||||||||
| F | 10 | Pre-op | PO | 4 mg | ||||||||
| 6 | Sablhok et al [15] | 2015 | India | NR | Parallel | A | 20 | NA(Control) | NA(Control) | NA(Control) | Class II B | |
| B | 20 | Post-op | PO | 4 mg | ||||||||
| C | 20 | Post-op | IM (Local) | 4 mg | ||||||||
| 7 | Gopalakrishnan et al. [16] | 2015 | India | 30 (NR) | Parallel | 22M;8F | A | 30 | Post-op | SM | 4 mg | NR |
| 20M;10F | B | 30 | NR | IM (unclear) | 4 mg | |||||||
| 8 | Saravanan et al. [17] | 2016 | India | NR | Parallel | NR | A | 20 | Pre-op | IM (unclear) | 4 mg | Class II A/B |
| B | 20 | Pre-op | SM | 4 mg | ||||||||
| C | 20 | NA(Control) | NA(Control) | NA(Control) | ||||||||
| 9 | Gopinath KA et al. [18] | 2017 | India | NR | Parallel | NR | A | 40 | Pre-op | SM | 4 mg | Pederson’s difficulty score of 5 to 10 were included |
| B | 40 | Pre-op | IV | 4 mg | ||||||||
| C | 40 | NA(Control) | NA(Control) | NA(Control) | ||||||||
| 10 | Kumar [19] | 2017 | India | 29 (NR) | Parallel | 9M;10F | A | 19 | Pre-op | SM | 4 mg | Class II/III A/B/C |
| 11M;8F | B | 19 | Pre-op | IV | 4 mg | |||||||
| 11 | Vivek et al. [20] | 2017 | India | 27 (NR) | Parallel | 28M;17F | A | 15 | Post-op | IV | 8 mg | Class II B |
| B | 15 | Post-op | SM | 8 mg | ||||||||
| C | 15 | Post-op | IM (unclear) | 8 mg | ||||||||
| 12 | Kaewkumnert S et al. [21] | 2019 | Thailand | 21.7(2.43) | Split-mouth | M13;F14 | A | 27 | Post-op | IO | 4 mg | Mesioangular/Horizontal |
| B | 27 | Post-op | SM | 4 mg | ||||||||
| 13 | Moranon et al. [22] | 2019 | Thailand | 21 (NR) | Split-mouth | M13;F17 | A | 30 | Pre-op | SLS | 8 mg | NR |
| B | 30 | Pre-op | PMS | 8 mg | ||||||||
| 14 | Mahmoud [23] | 2019 | Egypt | 27.6(4.8) | Parallel | M10;F5 | A | 15 | Pre-op | SM | NR | NR |
| 29.8(5.2) | 9M;6F | B | 15 | Pre-op | IM(Masseter) | NR | ||||||
| 28.5(5.9) | 9M;6F | C | 15 | Pre-op | IM(Systemic) | NR | ||||||
| 15 | Vivek et al. [5] | 2020 | India | 27 (NR) | Parallel | 38M;22F | A | 15 | Post-op | IV | 8 mg | Class II B |
| B | 15 | Post-op | SM | 8 mg | ||||||||
| C | 15 | Post-op | IM(Masseter) | 8 mg | ||||||||
| D | 15 | Post-op | PO | 8 mg | ||||||||
| 16 | Hiriyanna et al. [24] | 2020 | India | 28.67 (5.88) | Parallel | 20M;10F | A | 15 | Pre-op | SM | 8 mg | Class II/III A/B |
| 29.06 (5.73) | B | 15 | Pre-op | IV | 8 mg |
IV Intravenous; IM Intramuscular; PO Oral; IO Intraosseous; SL Sublingual; EA Endo-alveolar; SM Submucosal; Loc IM Local intramuscular (intramassetric); PMS Pterygomandibular space; VAS Visual analogue scale; M Male; F Female; SD Standard deviation; EA Endo-alveolar; IV Intravenous; IM Intramuscular; SM Submucosal; PO Peroral; PMS Pterygomandibular space; SLS Sublingual space; IO Intraosseous; NR Not reported; NA Not available